Pancreatic neuroendocrine tumors

Sun, Jian

doi:10.5582/irdr.2017.01007

Cited by 37 publications

(37 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While the percentage of PNENs in all pancreatic tumors is only 1% to 2%, the incidence has increased apparently in the past few years 4 , 5 . Meanwhile, the interest on pancreatic neuroendocrine neoplasms (pNENs) has grown 6 .…”

Section: Introductionmentioning

confidence: 99%

A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms

Gao

Wang

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Pancreatic neuroendocrine neoplasms (pNENs) are a group of clinically rare and heterogeneous diseases of the pancreas. However, the prognostic factors for this disease in patients still remain controversial. The purpose of our study is to evaluate the predictive roles of those prognostic factors for pNENs. All related articles published until Sep 17, 2017 were identified via PubMed, EMBASE, Web of Science, Ovid and the Cochrane Library. Studies that examined the prognostic factors of pNENs were enrolled. 17 articles (2822 patients) were finally included in this study. The pooled data suggested that patients with positive surgical resection margin and lymph node, advanced G stage and TMN stage, organ metastasis, vascular invasion and the necrosis of specimens had a decreased overall survival for pNENs. Similarly, patients with functional tumors might have a poor prognosis. However, age, gender, surgical type and size of tumor could not be regarded as prognostic factors for pNENs. Our analytic data demonstrated that surgical resection margin, G stage, TMN stage, lymph node, metastasis, vascular invasion and the necrosis could be prognostic factors for pNENs. Our study may assist doctors to screen patients with different prognosis more efficiently during follow-up and select appropriate treatment measures.

show abstract

Section: Introductionmentioning

confidence: 99%

A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms

Gao

Wang

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…pNETs comprise only 1% to 2% of all pancreatic neoplasms, and given the rarity of this tumor, well-designed randomized controlled trials on surgical treatment for pNET are not available [2, 3]. In addition to surgical, patient with advanced or metastatic pNETs requires a multidisciplinary approach, including targeted therapies, peptide receptor radiotherapy, local ablation and interventional therapy [3].…”

Section: Introductionmentioning

confidence: 99%

MEG3 Suppresses Human Pancreatic Neuroendocrine Tumor Cells Growth and Metastasis by Down-Regulation of Mir-183

Zhang

Feng

2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms which arise from pancreatic islet cells. Recently, lncRNA MEG3 has been reported as a tumor suppressor in variety cancers. This study aimed to reveal the functional effects of MEG3 on pNETs which has not been uncovered previously. Methods: The expression of MEG3, miR-183, and BRI3 in BON1 cells were altered by transfection with their specific vectors/shRNA, or mimic/inhibitor. Thereafter, cell viability, apoptosis, the protein expressions of cell cycle related factors, and apoptosis associated factors, as well as cell migration and invasion were respectively assessed by typan blue staining, flow cytometry, western blotting, and transwell assay. Results: MEG3 was low expressed in BON1 and QGP-1 cells, when compared to three normal cell lines (HEK293, CCL-153, and EC-304). MEG3 overexpression decreased BON1 cells viability, invasion, migration, but significantly induced apoptosis. miR-183 was a direct target of MEG3, and miR-183 up-regulation abolished the anti-growth and anti-metastasis effects of MEG3 overexpression on BON1 cells. Moreover, BRI3 was a target of miR-183, and BRI3 exhibited a tumor-promoting role possibly via activation of p38/ERK/AKT and Wnt/β-Catenin signaling in BON1 cells. Conclusion: This study demonstrated a tumor suppressive effect of MEG3 in BON1 cells that suppresses tumor cells growth and metastasis. A novel regulatory mechanism has been revealed that modulation of MEG3/miR-183/BRI3 axis may be pivotal in pNET.

show abstract

“…Streptozocin and fluorouracil have been the backbone of chemotherapy regiments for many years, with a response rate of over 60% and increase of survival by more than 1 year [21,22]. Chemotherapeutic regimens vary, according to tumour features, with cisplatin and etoposide being used for higher grade lesions [23] and temozolomide with capecitabine for well differentiated tumours [24]. Liposomal and conventional doxorubicin have also been used whereas addition of the antiangiogenesis monoclonal antibody Bevacizumab has been associated with a better progression free survival [25].…”

Section: Diagnostic and Therapeutic Challenges Of Nenmentioning

confidence: 99%

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours

Lykoudis

Partelli

Muffatti

et al. 2019

European Journal of Surgical Oncology

View full text Add to dashboard Cite

Pancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often indolent behaviour and particular diagnostic and therapeutic requirements. The specialized biochemical tests and radiological investigations, the complexity of surgical options and the variety of medical treatments that require individual tailoring, mandate a multidisciplinary approach that can be optimally achieved through an organized network. The present study describes currents concepts in the management of these tumours as well as an insight into the challenges of delivering the pathway in and outside a Network.

show abstract

Pancreatic neuroendocrine tumors

Cited by 37 publications

References 67 publications

A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms

A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms

MEG3 Suppresses Human Pancreatic Neuroendocrine Tumor Cells Growth and Metastasis by Down-Regulation of Mir-183

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours

Contact Info

Product

Resources

About